BRAF and non-small cell lung carcinoma: Regarding the less common genomic alterations, the percentages for baseline BM and throughout the history of the disease are as follows: BRAF V600E mutations are 31% (14) and not reported (possibly due to the low prevalence of BRAF mutations in NSCLC), HER2 mutations are 14% and 28% (15, 16), RET rearrangements are 25% and 46% (17), and KRAS mutations are (G12C and non-G12C) 24% and 35.1% (15, 18).